Posts Tagged ‘diabetes’

New Jersey Is Sued Over the Forced Medication of Patients at Psychiatric Hospitals

Tuesday, August 3rd, 2010

New York Times
by Richard Perez-Pena
August 3, 2010

Patient advocates filed a federal lawsuit on Tuesday charging that New Jersey psychiatric hospitals routinely medicate patients against their will without a review by an outside arbiter, a practice that is banned in most other states.

Twenty-nine states require a judge’s ruling for involuntary medication, according to the suit, including New York, Connecticut and other large states, like California, Florida and Texas. Five other states leave the decision to an individual or panel outside the hospital. Some states also provide an advocate to represent a patient in a hearing on forced medication.

But in New Jersey, state rules allow a patient in a state hospital to appeal medication decisions only to people in the hospital. The lawsuit contends that the internal appeal process is routinely ignored and that psychiatric patients in private hospitals lack any opportunity to appeal medication regimens at all.

The suit, filed in Federal District Court in Trenton by the group Disability Rights New Jersey, seeks a court order requiring the state to provide judicial review of involuntary medication. It notes that a prison inmate has more power to contest treatment decisions than a psychiatric patient.

The drugs forced on patients include powerful medications for conditions like schizophrenia and bipolar disorder. They help many people with those diseases function better, but can have serious side effects, including diabetes, tremors, seizures, high blood pressure, obesity, sedation, aches and impaired mental function.

“As a patient in a state hospital, it’s your legal right to refuse and go through a process, but you get severely penalized if you try,” said W. Emmett Dwyer, litigation director of Disability Rights New Jersey, a federally financed organization. “They view you as noncompliant with treatment. They give you an injection instead of a pill. And they tell you if you don’t take it, you won’t get out.”

There are about 1,800 patients at any given time in New Jersey’s five state psychiatric hospitals, and 1,000 in private ones.

Michael D. Reisman, a lawyer with Kirkland & Ellis, which is helping bring the lawsuit, said recent records from one state hospital showed that fewer than 20 percent of patients contested their medication.

But the advocates and several former patients said many more objected to their prescriptions but submitted quietly, rather than risk painful injections or a longer hospital stay. Others, they said, are too medicated to object.

“When I said no, they just shot me up instead, so pretty soon I gave up,” said Alice Hsia, 34, who has been in and out of hospitals for schizophrenia. “The times I was sedated, I would sign anything they wanted.”

Mr. Reisman said the question often was not whether some medication was needed, but rather one of dosage or a desire to try a “different drug with fewer side effects.” Some hospital

psychiatrists do not take such concerns seriously, he said, but “a judicial hearing would give the patient more leverage and force the doctors to listen.”

The State Department of Human Services, which runs the hospitals, declined to comment on the suit. But among advocates for the mentally ill, there are wide-ranging opinions on involuntary treatment.

Phil Lubitz, associate director of the National Alliance on Mental Illness of New Jersey,  said he did not see forced medication as a major issue, noting that it was extremely difficult to get patients committed in New Jersey, and that most who were presented “a danger to themselves or others.”

But Robert Davison, executive director of the Mental health Association of Essex County,  called New Jersey’s policy “beneath contempt.”

Yana Paskova for The New York Times

Joseph Cichowski said he would have challenged forced medication if he had the opportunity.

Nicole Bengiveno/The New York Times

Alice Hsia said she submitted to prescriptions at hospitals quietly rather than risk painful injections.

Read the entire article here: http://www.nytimes.com/2010/08/04/health/policy/04psych.html

« Return to news items


  • Share/Bookmark

Drug maker to settle 200 lawsuits for failing to warn patients of diabetes risks caused by its antipsychotic drug

Friday, July 23rd, 2010

AboutLawsuits.com
July 23, 2010

AstraZeneca has agreed to settle Seroquel lawsuits filed by about 200 people who claim that the drug maker failed to adequately warn about the risk of diabetes and other side effects of their antipsychotic drug. The Seroquel settlements are reportedly the first payments AstraZeneca has made out of an estimated 26,000 claims that have been presented against the company.

Bloomberg News reports that AstraZeneca has agreed to pay $2 million as a settlement for the Seroquel lawsuits, which comes out to an average of about $10,000 per claim. It is not clear what injuries were involved in these claims, or what the circumstances are for the cases. All of the settled lawsuits involved plaintiffs represented by one attorney, and Bloomberg News reports that the agreement came as a result of court-ordered mediation.

Although AstraZeneca has previously indicated that they would fight all Seroquel cases at trial, company officials now indicate that they will continue to negotiate with plaintiffs’ attorneys.

Seroquel (quetiapine fumarate) is an atypical-antipsychotic that is a top selling drug for AstraZeneca, generating nearly $5 billion a year in sales. Originally approved by the FDA in 1997 for the treatment of schizophrenia, it has been frequently prescribed off-label for uses that were not approved as safe and effective at the time, such as anxiety, obsessive dementia, compulsive disorders and autism.

In July 2006, all Seroquel lawsuits filed in federal courts throughout the United States were consolidated for pretrial litigation before U.S. District Judge Anne Conway in the Middle District of Florida as part of a multidistrict litigation (MDL). In May of this year, Judge Conway determined that the majority of the work in the Seroquel litigation was complete, and began remanding cases back to the original jurisdiction where they were filed for trial.

Read entire article:  http://www.aboutlawsuits.com/settlement-for-seroquel-lawsuits-reached-in-some-cases-11647/

« Return to news items


  • Share/Bookmark

BNET: ‘The Dog Ate AstraZeneca’s Homework! Evidence on Misleading Drug Ad Disappears From Company’s Files’

Wednesday, July 7th, 2010

BNET
By Jim Edwards
July 7, 2010

AstraZeneca (AZN) says it has lost a crucial internal document that would explain how an ad for its antipsychotic Seroquel misleadingly claimed there was “no weight gain” with the drug and described its “favorable weight profile.” But the company admits it kept the six-year-old envelope that once allegedly contained the ad’s approval certificate, according to a ruling by the U.K.’s Prescription Medicines Code of Practice Authority.

The drug industry watchdog also alleges AZ’s Seroquel management team “pressured and manipulated” executives around them in order to make sure negative data on Seroquel was buried. The PMCPA ruled that AZ had breached its code of practice, which requires companies to operate in “a professional, ethical and transparent” manner.

If there’s a lesson here for managers, it’s this: Simply winning the legal war isn’t good enough. Consumers — and your own employees, as the Seroquel case shows — expect companies to go above and beyond. (AZ has mostly won the litigation filed against it which alleges the company failed to warn patients that Seroquel causes weight gain and diabetes. It settled with the Department of Justice for $520 million.)

Many of the allegations in the PMCPA case are familiar, but what’s new is the source: One of the complainants was an unnamed male former AZ executive, employed at the company from 1992 to 2001, who from 1995 to 2000 was responsible for the medical aspects of the U.K. launch and subsequent marketing of Seroquel.*

In terms of the ad, the BBC reported in January that AZ had published a misleading ad in the British Journal of Psychiatry in April 2004. The PMCPA asked AZ to produce all the documentation behind the ad. Here’s its characterization of AZ’s response:

… for a product that had been marketed for more than 12 years in the UK, the company did not believe that it could reasonably investigate and respond to such a broad request in relation to specific clauses of the code.

The Code requires companies keep relevant documents for three years, AZ argued, and the ad itself was at least five years old, thus, “AstraZeneca had been unable to produce the certificate approving the advertisement from its archive.” But:

The Appeal Board noted from the AstraZeneca representatives at the appeal that although the job bag for the advertisement at issue still existed, it did not contain the relevant certificate.

How unfortunate!

More seriously, the PMCPA appeared to take seriously the ex-employee’s allegation that AZ buried or manipulated data on Seroquel long after the company became aware of weight-gain effects on its patients. The executive alleged that in 1997 he was told by a colleague…

Read entire article here:  http://industry.bnet.com/pharma/10008835/the-dog-ate-astrazenecas-homework-evidence-on-misleading-drug-ad-dissappears-from-companys-files/

« Return to news items


  • Share/Bookmark

AstraZeneca Denied Antipsychotic Drug’s Link to Diabetes for Years After Admitting Link to Japanese Physicians

Thursday, June 17th, 2010

Natural News
By David Gutierrez
June 17, 2010

Drug giant AstraZeneca attempted to obscure the connection between one of its blockbuster drugs and diabetes risk for years after it knew of the problem, according to documents recently unsealed as part of lawsuits against the company.

More than 15,000 patients have sought damages from the company, alleging that they were harmed by side effects from its atypical antipsychotic Seroquel. According to the plaintiffs, AstraZeneca deliberately hid information linking the drug to an increased risk of weight gain and diabetes. The lawsuits have been consolidated into a single case for the purpose of pre-trial proceedings.

The recently unsealed documents include notes from a meeting between salesperson Nancy White and a doctor in July 2006, during which the doctor said that his patients were expressing concern about Seroquel’s links to diabetes. White reported telling the doctor that “there has been no causative effect” proven between the drug and the disease.

Yet in November 2002, AstraZeneca had issued a warning to doctors in Japan that due to dozens of reports linking Seroquel to diabetes, “causality with the drug could not be ruled out.” The company cautioned doctors not to prescribe the drugs to diabetics and to encourage all Seroquel patients to monitor their blood sugar. Just over a year later, the company issued a similar warning to doctors in the United States.

Read entire article:  http://www.naturalnews.com/029012_AstraZeneca_diabetes_drug.html

« Return to news items


  • Share/Bookmark

“Drugging Pre-School Children: A crime against childhood—children as young as 2 prescribed powerful anti-psychotics”

Thursday, June 10th, 2010

The MetroWest Daily News
By Jacob Azerrad
June 10, 2010

In 2001, Harry Markopolos repeatedly warned the authorities about Bernie Madoff. No one listened. Only a serious downturn in the economy led to Madoff’s downfall. It’s not a Ponzi scheme, but once again, no one is listening and the red flags are everywhere. This time the victims are our very young, innocent children in the millions. Today, children as young as 2, are being prescribed powerful anti-psychotic medications. Side effects include tics, drooling, and incessant eating. Some children have gained up to 100 pounds and often progress to becoming diabetic.

Virtually nothing is known about the long-term impact of these medications. And no one seems to care. Certainly not the drug companies pushing these drugs, nor the doctors who have been coerced by the pharmaceutical industry and panicking parents alike into prescribing them. The increase in the use of anti-psychotics is directly tied to the rising incidence of one particular diagnosis, bipolar disorder. Experts estimate that the number of kids with this diagnosis is now more than one million and rising, making it more common than autism and diabetes combined. To treat it, doctors are administering medications that have yet to be approved for children. Mothers are legally medicating their two-year-olds with Risperdal to quiet their tantrums, Trileptal to stabilize their moods, and Clonidine to help them sleep.

This is not the old story about ADD or ADHD and the use of Ritalin or other approved drugs in use since the 1970′s. This is not about helping the child who fidgets and can’t concentrate in their elementary school classroom. This is about tens of thousands of energetic, outgoing, healthy, and normal 3- and 4-year-olds who just won’t sit still in Mommy and Me. It is those children who have now been diagnosed with a new and controversial diagnosis – Childhood Bipolar Disorder.

On Sept. 4, 2007, The New York Times stated that studies in the 1970s and 80s concluded bipolar disorder was rare in children, but between 1994 to 2003, there was an astounding 40-fold increase in the number of children diagnosed with bipolar disorder.

In a 2007 “60 Minutes” episode, Katie Couric focused on the short life of 4-year-old Rebecca Riley of Hull. Diagnosed with bipolar disorder at age 28 months, she was dead one year later from an overdose of a psychotropic drug cocktail. At one point, Couric asks Rebecca’s mother, who had been charged with her daughter’s murder, if she thought her child’s behavior might have been normal. That in fact, maybe little Rebecca was just exhibiting Terrible Two’s behavior.

On Nov. 19, 2008, the New York Times reported that 31 children who were diagnosed with Childhood Bipolar Disorder and given the drug Risperdal for tantrums died, and 1,176 suffered serious side effects.

Read entire article:  http://www.metrowestdailynews.com/opinion/x1602634540/Azerrad-Drugging-pre-school-children-A-crime-against-childhood

« Return to news items


  • Share/Bookmark

42 percent of all kids in foster care are taking three or more mood-altering drugs

Monday, June 7th, 2010

NewsTimes.com
By Eileen FitzGerald
June 7, 2010

Here’s just one statistic that Danbury school psychologist Charles Manos worries about: 42 percent of all kids in foster care are taking three or more mood-altering drugs.

“All kids in foster care have some story of trauma, like abuse or neglect, so we need to ask the question `How are we dealing with trauma?’” Manos asked.

Overall, children are receiving more prescriptions than ever before to treat medical, emotional and psychological problems, according to a May report from Medco Health Solutions.

More than one in four children with health insurance in the U.S., and nearly 30 percent of all children from 10 to 19, take at least one prescription to treat a chronic condition. The most substantial increases over the past nine years have been in antipsychotic, diabetes and asthma drugs, according to the Medco report.

In some cases, students take medications at home. In many cases, school nurses dispense it.

For instance, Danbury schools health coordinator Sue Levasseur said 80 middle school students receive asthma medication each day at school and another 14 to 15 children receive a psychotropic drug at school.

Part of the school system’s job is to educate parents, said Manos, who has worked in local schools for more than 30 years and also has a private practice.

“I think we have become a society that says it’s OK to medicate the symptoms of kids. Medication is easier. I think as a society we are quick to change behavior rather than understand it,” Manos said.

Behavior medications can be destructive if used improperly, he said.

“Say there is abuse or trauma, and we don’t do an adequate analysis. Then we silence the symptoms through the medications,” Manos said.

“The fact is that medication does not treat a disorder, it treats the symptoms of the manifestation, and people don’t understand that. I think there is a myth that medication treats the disorder.”

Read entire article:  http://www.newstimes.com/news/article/Growing-numbers-of-children-on-medication-514614.php

« Return to news items


  • Share/Bookmark

A good start: Antipsychotic drug maker to pay half billion in fines for illegal marketing

Thursday, May 20th, 2010

FoodConsumer
By Dr. Mercola
May 20, 2010

Drugmaker AstraZeneca has agreed to pay $520 million to settle federal investigations into marketing practices for its schizophrenia drug Seroquel. This makes AstraZeneca the fourth big drug company in the last three years to admit to federal charges of illegal marketing of antipsychotic drugs.

The company was accused of misleading doctors and patients by spotlighting favorable research while failing to adequately disclose studies showing that Seroquel increases the risk of diabetes.

The New York Times reports that:

“AstraZeneca still faces more than 25,000 civil lawsuits filed on behalf of patients contending that the company did not disclose the drug’s risks.”

Dr. Mercola’s Comments:

The illegal and unsafe actions of drug companies make headlines yet again as AstraZeneca agrees to pay a $502 million fine to settle the federal charges of using illegal marketing tactics to drive up sales of its blockbuster drug Seroquel.

Although this sounds like a lot of money, it’s little more than a symbolic slap on the wrist when you consider how much money they’ve made from the drug already. According to the New York Times, the antipsychotic drug Seroquel pulled in $4.9 BILLION in sales last year!

You see from the company’s perspective it’s merely another cost of doing business.  For every dollar they are fined they are making ten. While not all of their profit was due to their illegal marketing practices, the fine was only a one-time fine, while revenues have poured in over many years and will continue to do so in the future, as a result of these illegal activities.

Read entire article:  http://www.foodconsumer.org/newsite/Non-food/Drug/drug_company_illegal_marketing_20-5100730.html

« Return to news items


  • Share/Bookmark

New York Magazine: Shrink Revolt—The controversy over psychiatric diagnoses and the DSM continues

Monday, April 26th, 2010

New York Magazine
By Jennifer Senior
April 25, 2010

Two Jews may, as the saying goes, have three opinions, but that appears to be a fairly modest ratio when compared with psychiatrists. It was inevitable that revisions to the Diagnostic and Statistical Manual of Mental Disorders would invite controversy—it’s the classic reference work for mental-health professionals, and a convenient field guide to understanding crazy exes for the rest of us—but even the American Psychiatric Association, which first appointed the work groups to update the text two years ago, couldn’t have predicted the squabbles now under way. Dr. Allen Frances, the man who chaired the task force that created the current edition (the DSM-IV), has today emerged as the most trenchant, and relentless, critic of the proposed revisions to the upcoming edition (the DSM-5; among the changes is a transition to Arabic numerals). Last Tuesday was the final day those revisions were open to public comment. “And hopefully,” Frances says, “most of them will drop out.”

Basically, Frances believes that the first draft of the DSM-5 is too promiscuous with its labels, both by loosening diagnostic criteria and by introducing a host of new and, to his mind, problematic maladies—like Binge Eating Disorder (more or less defined as gorging on massive amounts at least once a week for three months). By the estimate of one DSM-5 task-force member, Frances says, this disorder already afflicts 6 percent of the population. “And that,” he notes, “is before drug companies start marketing something for it.”

As Frances pointed out in a recent Los Angeles Times editorial, such taxonomic adjustments only seem to further shrink “the ever-shrinking domain of the normal.” Take another DSM-5 proposed addition: Temper Dysregulation Disorder With Dysphoria. Frances fears this may be deployed for kids who have typical temper problems. Or Major Depressive Episode: As it’s redefined, it could now be used to describe someone who’s spent two weeks grieving over a lost spouse, he contends. But the worst offender, in Frances’s view, is Psychosis Risk Syndrome, which attempts to identify and treat youngsters before they become psychotic. In his view, there isn’t any evidence that early intervention with medication helps, while there’s plenty to suggest that many teens could be misidentified. “And that I saw as a public-health danger,” he says, “because there are real drawbacks to being on antipsychotics.” Like weight gain and diabetes. “Those children are also disproportionately on Medicaid,” he adds.

Read entire article:  http://nymag.com/news/intelligencer/65632/

« Return to news items


  • Share/Bookmark

On Earth Day, with Green Causes in the Forefront, Here is a Video about Green Mental Health

Thursday, April 22nd, 2010

Psychiatry’s solution to life’s problems is stigmatizing psychiatric labels and the administration of toxic drugs which international drug regulatory agencies have warned can cause mania, worsening depression, anxiety, delusions, seizures, liver failure, suicide, mania, heart attack, stroke, fatal blood clots, sudden death, diabetes and much more.

(See http://www.cchrint.org/psychdrugdangers/)

Green Mental Health Care is a non-toxic, non-addictive and non-invasive approach to mental health which focuses on workable medical, not psychiatric, solutions that have better patient outcomes and are not harmful or toxic to those seeking help.  The focus is on finding underlying medical causes that can manifest as psychiatric “symptoms” without  the need for subjective psychiatric labels and deadly drugs.  For more information on medical alternatives to toxic drugs, visit  http://www.cchrint.org/alternatives/

View video on Green Mental Health here.

« Return to news items


  • Share/Bookmark

Psychiatric Drugging of Infants and Toddlers—The U. S. has become the psychiatric drugging capital of the world

Tuesday, April 20th, 2010

CounterCurrents.org
By Evelyn Pringle
April 19, 2010

The United States has become the psychiatric drugging capital of the world for kids with children being medicated at a younger and younger age. Medicaid records in some states show infants less than a year old on drugs for mental disorders.

The use of powerful antipsychotics with privately insured children, aged 2 through 5 in the US, doubled between 1999 and 2007, according to a study of data on more than one million children with private health insurance in the January, 2010, “Journal of the American Academy of Child & Adolescent Psychiatry.”

The number of children in this age group diagnosed with bipolar disorder also doubled over the last decade, Reuters reported.

Of antipsychotic-treated children in the 2007 study sample, the most common diagnoses were pervasive developmental disorder or mental retardation (28.2%), ADHD (23.7%), and disruptive behavior disorder (12.9%).

The study reported that fewer than half of drug treated children received a mental health assessment (40.8%), a psychotherapy visit (41.4%), or a visit with a psychiatrist (42.6%) during the year of antipsychotic use.

“Antipsychotics, which are being widely and irresponsibly prescribed for American children–mostly as chemical restraints–are shown to be causing irreparable harm,” warned Vera Hassner Sharav, president of the Alliance for Human Research Protection, in a February 26, 2010 InfoMail.

“These drugs have measurable severe hazardous effects on vital biological systems, including: cardiovascular adverse effects that result in shortening lives; metabolic adverse effects that induce diabetes and the metabolic syndrome,” she wrote. “Long-term use of antipsychotics has been shown to result in metabolic syndrome in 40% to 50% of patients.”

The lead researcher on the study above, Columbia University psychiatry professor Mark Olfson, told Reuters that about 1.5% of all privately insured children between the ages of 2 and 5, or one in 70, received some type of psychiatric drug in 2007, be it an antipsychotic, a mood stabilizer, a stimulant or an antidepressant.

Psychiatric drugs bathe the brains of growing children with agents that threaten the normal development of the brain, according to Dr Peter Breggin, founder of the International Center for the Study of Psychiatry and Psychology (ICSPP), and author of about 20 books, including “Medication Madness.”

Read entire article:  http://www.countercurrents.org/pringle190410.htm

« Return to news items


  • Share/Bookmark